Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

被引：0
作者：
H Chang
X Y Qi
S Samiee
Q-L Yi
C Chen
S Trudel
J Mikhael
D Reece
A K Stewart
机构：
[1] Princess Margaret Hospital/University Health Network,Department of Laboratory Hematology
[2] University of Toronto,Department of Laboratory Medicine and Pathobiology
[3] Princess Margaret Hospital/University Health Network,Department of Medical Oncology
[4] University of Toronto,Department of Biostatistics
[5] Princess Margaret Hospital/University Health Network,undefined
[6] University of Toronto,undefined
[7] Princess Margaret Hospital/University Health Network,undefined
[8] University of Toronto,undefined
来源：
Bone Marrow Transplantation | 2005年 / 36卷
关键词：
multiple myeloma; IgH translocations; 13q deletions; p53 deletions; fluorescence ; hybridization; autologous stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.
引用
收藏
页码：793 / 796
页数：3
相关论文
共 38 条
[1]  
Avet-Loiseau H(1999)High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence Genes Chromosomes Cancer 24 9-15
[2]  
Brigaudeau C(2002) hybridization Oncogene 20 5611-5622
[3]  
Morineau N(2002)Chromosome translocations in multiple myeloma Blood 100 1579-1583
[4]  
Bergsagel PL(2004)Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Br J Haematol 125 64-68
[5]  
Kuehl WM(2005)The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant Blood 105 358-360
[6]  
Moreau P(2004)P53 gene deletion detected by fluorescence Leuk Lymphoma 45 965-969
[7]  
Facon T(1996) hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation N Engl J Med 335 91-97
[8]  
Leleu X(2003)Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis N Engl J Med 348 1875-1883
[9]  
Chang H(2004)A prospective, randomized trail of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma Blood 103 20-32
[10]  
Sloan S(2002)Medical research council adult leukaemia working party. High-dose chemotherapy and hematopoietic stem-cell rescue for multiple myeloma Blood 99 2185-2191
1234